Phase 1b Keynote-013 Study of Pembrolizumab in Patients With Classic Hodgkin Lymphoma After Brentuximab Vedotin Failure: Results of >4 Years of Follow-Up

Hematological Oncology - United Kingdom
doi 10.1002/hon.106_2630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Investigating Safety and Preliminary Efficacy of Afm13 Plus Pembrolizumab in Patients With Relapsed/Refractory Hodgkin Lymphoma After Brentuximab Vedotin Failure

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase 1b Study of Pembrolizumab in Patients With Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (Rrpmbcl): Updated Results From the Keynote-013 Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Brentuximab Vedotin Followed by ABVD +/− Radiotherapy in Patients With Previously Untreated Hodgkin Lymphoma: Final Results of a Pilot Phase II Study

Haematologica
Hematology
2015English

Phase 1b Trial of Pembrolizumab Monotherapy for Relapsed/Refractory Multiple Myeloma: KEYNOTE ‐013

British Journal of Haematology
Hematology
2019English

Pembrolizumab Monotherapy in Patients With Primary Refractory Classical Hodgkin Lymphoma: Subgroup Analysis of the Phase 2 Keynote-087 Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

First Salvage Treatment With Bendamustine and Brentuximab Vedotin in Hodgkin Lymphoma: A Phase 2 Study of Fil Onlus

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure – Polish Lymphoma Research Group Real-Life Experience

Acta Haematologica Polonica
OncologyHematology
2018English

Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin

British Journal of Haematology
Hematology
2018English

BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy